http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2010118448-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39533 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2008-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2010118448-A |
| titleOfInvention | COMBINED THERAPY BY ANTIBODIES ANTI-CD20 TYPE II IN COMBINATION WITH ACTIVE AGENT ANTI-BCL-2 |
| abstract | 1. The use of an anti-CD20 type II antibody for the manufacture of a medicament for the treatment of cancer expressing CD20 in combination with an anti-Bcl-2 active agent. ! 2. Use of an anti-CD20 type II antibody for the manufacture of a medicament for treating a patient suffering from cancer expressing CD20 in combination with an anti-Bcl-2 active agent. ! 3. The use according to any one of claims 1 to 2, characterized in that the ratio of the binding activities of the indicated anti-CD20 type II antibody and rituximab against CD20 on Raji cells (ATCC No. CCL-86) is from 0.3 to 0.6 . ! 4. The use according to claim 1 or 2, characterized in that said anti-CD20 type II antibody is a humanized B-Ly1 antibody. ! 5. The use according to claim 1 or 2, characterized in that the indicated anti-CD20 type II antibody possess increased antibody-dependent cell-mediated cytotoxicity (ASCOT). ! 6. The use according to claim 1 or 2, characterized in that at least 40% or more of the oligosaccharides in the Fc region of said anti-CD20 type II antibodies are unfucosylated. ! 7. The use according to claim 1 or 2, characterized in that the specified anti-Bcl-2 active agent is selected from the group consisting of oblimersen, SPC-2996, RTA-402, gossypol, AT-101, obatoclax mesylate, A-371191, A-385358, A-438744, ABT-737, AT-101, BL-11, BL-193, GX-15-003, 2-methoxyantimycin A3, HA-14-1, KF-67544, purpurogallin, TP-TW -37, YC-137 and Z-24, preferably from the group consisting of ABT-263 and ABT-737. ! 8. The use according to claim 1 or 2, characterized in that said active anti-Bcl-2 agent is an inhibitor of the binding of Bcl-2 protein to anti-Bcl-2 and is characterized by an IC50 value of 5 μM or less. ! 9. The use of claim 8, characterized in that said Bcl-2 protein binding inhibitor |
| priorityDate | 2007-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 27.